18 terminated. 18 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Terminated 18 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Type 2 Diabetes: new trials by email Literature Review of Type 2 Diabetes trials Research Report on Type 2 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes LY3549492, Placebo - Obesity, Overweight | Phase 2 | Terminated | Eli Lilly and Company | 1 | 2025-06-19 | 2026-08-31 |
| Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes DS102, Placebo - Hypertriglyceridemia, Type 2 Diabetes | Phase 2 | Terminated | Afimmune | 233 | 2020-10-13 | 2023-06-12 |
| Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) Neo-Kidney Augment - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Terminated | Prokidney | 1 | 2016-07-01 | 2021-04-23 |
| An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Obesity, Type 2 Diabetes | Phase 2 | Terminated | Zafgen, Inc. | 152 | 2014-12-01 | 2016-01-06 |
| Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes ISIS-APOCIIIRX, Placebo - Type 2 Diabetes | Phase 2 | Terminated | Ionis Pharmaceuticals, Inc. | 15 | 2012-07-01 | 2022-01-18 |
| A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus RTA 402 - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Terminated | Kyowa Kirin Co., Ltd. | 11 | 2012-02-01 | 2017-03-03 |
| A Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus RTA 402 - Chronic Kidney Disease, Type 2 Diabetes | Phase 2 | Terminated | Kyowa Kirin Co., Ltd. | 53 | 2012-02-01 | 2017-03-03 |
| Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects EV-077, Placebo - Type 2 Diabetes | Phase 2 | Terminated | Evolva SA | 33 | 2012-01-01 | 2013-06-17 |
| Effect of GLP-1 on Insulin Biosynthesis and Turnover Rates glucagon like peptide-1, glucose control - Type 2 Diabetes | Phase 1 / Phase 2 | Terminated | Albert Einstein College of Medicine | 20 | 2010-08-12 | 2024-02-28 |
| Hypogonadism in Young Men With Type 2 Diabetes testosterone, clomiphene, placebo - Hypogonadotropic Hypogonadism, Type 2 Diabetes | Phase 2 | Terminated | State University of New York at Buffalo | 5 | 2010-06-01 | 2019-10-04 |
| The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes Resonator device, Resonator device - sham - Type 2 Diabetes | Phase 2 | Terminated | pico-tesla Magnetic Therapies, LLC | 165 | 2009-09-01 | 2011-05-05 |
| Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes INCB019602, Placebo, Metformin - Type 2 Diabetes | Phase 2 | Terminated | Incyte Corporation | 48 | 2008-05-01 | 2012-10-30 |
| Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients DIO-902 - Type 2 Diabetes | Phase 2 / Phase 3 | Terminated | DiObex | 150 | 2008-01-01 | 2008-05-28 |
| A Phase 2b Study of DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvastatin or Atorvastatin Placebo for Type 2 Diabetes DIO-902, DIO-902 placebo - Type 2 Diabetes | Phase 2 | Terminated | DiObex | 200 | 2007-07-01 | 2008-11-13 |
| Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study Fenofibrate, Metformin, Placebo - Type 2 Diabetes, Dyslipidemia | Phase 2 / Phase 3 | Terminated | Solvay Pharmaceuticals | 8 | 2006-10-01 | 2008-08-13 |
| ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity Tesaglitazar, Metformin, Dietary and lifestyle modification counseling - Type 2 Diabetes | Phase 2 | Terminated | AstraZeneca | 105 | 2005-08-01 | 2008-03-17 |
| Dose Response Study in Japanese Patients Tesaglitazar - Type 2 Diabetes | Phase 2 | Terminated | AstraZeneca | 250 | 2004-05-01 | 2009-04-22 |
| Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy nitroaspirin - Type 2 Diabetes, Early Nephropathy | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 13 | 2003-03-01 | 2015-04-09 |
Diabetes Mellitus, Type 2 (18) · Diabetes Mellitus (3) · Renal Insufficiency, Chronic (3) · Insulin Resistance (2) · Obesity (2) · Dyslipidemias (1) · Hypertriglyceridemia (1) · Hypogonadism (1) · Kidney Diseases (1) · Overweight (1)
Endocrine System Diseases (18) · Glucose Metabolism Disorders (18) · Metabolic Diseases (18) · Nutritional and Metabolic Diseases (18) · Diabetes Mellitus (15) · Pathological Conditions, Signs and Symptoms (5) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Male Urogenital Diseases (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Chronic Disease (3) · Disease Attributes (3) · Kidney Diseases (3) · Pathologic Processes (3)
Metformin (3) · tesaglitazar (2) · CKD732 (1) · Clomiphene (1) · Diet (1) · Fenofibrate (1) · Glucagon-Like Peptide 1 (1) · Glycemic Control (1) · Incretins (1) · Testosterone (1) · epeleuton (1) · nitroaspirin (1)
AstraZeneca (2) · DiObex (2) · Kyowa Kirin Co., Ltd. (2) · Afimmune (1) · Albert Einstein College of Medicine (1) · Eli Lilly and Company (1) · Evolva SA (1) · Incyte Corporation (1) · Ionis Pharmaceuticals, Inc. (1) · Mario Negri Institute for Pharmacological Research (1) · Prokidney (1) · Solvay Pharmaceuticals (1) · State University of New York at Buffalo (1) · Zafgen, Inc. (1) · pico-tesla Magnetic Therapies, LLC (1)
United States (10) · Australia (3) · Italy (3) · Japan (3) · Finland (2) · Germany (2) · New Zealand (2) · Argentina (1) · Georgia (1) · Ireland (1) · Israel (1) · Latvia (1) · Switzerland (1) · United Kingdom (1)
Ashley Johns, MSHS (1) · Daniel T Stein, MD (1) · Dennis Kim, MD (1) · Markus Weissbach, MD (1) · Piero Ruggenenti, MD (1) · Sandeep Dhindsa, MBBS (1) · Sherwyn Schwartz, MD (1) · Thomas Jax, MD (1) · William V Williams, MD (1)
2005 (1), R01DK061644 (1)